Automate Your Wheel Strategy on QGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including QGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QGEN
- Rev/Share 9.5484
- Book/Share 16.8276
- PB 2.5654
- Debt/Equity 0.5829
- CurrentRatio 2.6001
- ROIC 0.0639
- MktCap 9360534609.0
- FreeCF/Share 2.2007
- PFCF 19.6129
- PE 23.0956
- Debt/Assets 0.3246
- DivYield 0.0292
- ROE 0.1148
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | QGEN | Barclays | -- | Overweight | -- | $55 | June 24, 2025 |
| Downgrade | QGEN | Redburn Atlantic | Buy | Neutral | -- | -- | April 4, 2025 |
| Downgrade | QGEN | Robert W. Baird | Outperform | Neutral | $52 | $42 | Feb. 19, 2025 |
| Downgrade | QGEN | Morgan Stanley | Overweight | Equal Weight | -- | $48 | Jan. 6, 2025 |
| Upgrade | QGEN | Jefferies | Hold | Buy | $42.5 | $54 | Dec. 10, 2024 |
| Downgrade | QGEN | HSBC Securities | Buy | Hold | -- | $49 | Oct. 17, 2024 |
News
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Seattle's Parse Biosciences to be acquired by Qiagen for $225M
Published: November 06, 2025 by: GeekWire
Sentiment: Positive
Seattle's Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a $225 million cash
Read More
Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. ( QGEN ) Q3 2025 Earnings Call November 5, 2025 9:30 AM EST Company Participants John Gilardi - VP & Head of Corporate Communications Thierry Bernard - CEO, MD & Member of Management Board Roland Sackers - CFO, MD & Member of Management Board Conference Call Participants Jack Meehan - Nephron Research LLC Hugo Solvet - BNP Paribas, Research Division Douglas Schenkel - Wolfe Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Aisyah Noor - Morgan Stanley, Research Division Patrick Donnelly - Citigroup Inc., Research Division Luke Sergott - Barclays Bank PLC, Research Division Jan …
Read More
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
Published: November 04, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its adjusted diluted EPS target to about $2.38 CER (previously about $2.35 CER). QIAGEN also expects an adjusted opera.
Read More
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
Published: November 04, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands & SEATTLE--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN's Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and bi.
Read More
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. (NYSE:QGEN ) Bank of America Global Healthcare Conference 2025 September 25, 2025 5:45 AM EDT Company Participants John Gilardi - VP & Head of Corporate Communications Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks for joining us.
Read More
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Read More
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
Read More
QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
Published: August 28, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net share settle.
Read More
Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Published: August 21, 2025 by: Seeking Alpha
Sentiment: Positive
Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low leverage, providing a resilient investment option amid sector volatility and macroeconomic uncertainty. While Qiagen is a strong short-term buy, investors should also consider peers like SysMex, BioMerieux, and CellaVision for diversification and growth potential.
Read More
Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Examine the evolution of Qiagen's (QGEN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Read More
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. (NYSE:QGEN ) Q2 2025 Earnings Conference Call August 6, 2025 9:30 AM ET Company Participants John Gilardi - Vice President of Corporate Communications & Investor Relations Roland Sackers - CFO, MD & Member of Management Board Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Casey Rene Woodring - JPMorgan Chase & Co, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Harry MacKinnon Gillis - Joh.
Read More
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
QGEN or EXAS: Which Is the Better Value Stock Right Now?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Here's Why Qiagen (QGEN) is a Strong Value Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Qiagen (QGEN) Just Flashed Golden Cross Signal: Do You Buy?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, QIAGEN N.V. (QGEN) is looking like an interesting pick, as it just reached a key level of support.
Read More
Here's Why Qiagen (QGEN) is a Strong Growth Stock
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Read More
QGEN Stock Rises in After Market Following Partnership With Incyte
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Read More
Should You Add QIAGEN Stock to Your Portfolio for Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Negative
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Read More
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Read More
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Qiagen (QGEN) is a Strong Value Stock
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
Read More
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN's reach in MRD testing and cover solid tumors and hematological cancers.
Read More
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.
Read More
About Qiagen N.V. (QGEN)
- IPO Date 1996-06-28
- Website https://www.qiagen.com
- Industry Medical - Diagnostics & Research
- CEO Thierry Bernard
- Employees 5700